# Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

> **NCT00032799** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 905 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** natalizumab

## Key facts

- **NCT ID:** NCT00032799
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 905 (ACTUAL)
- **Last updated:** 2016-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032799, "Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00032799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*